Frazier Life Sciences Management, L.P. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001892134
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2023 · 49 positions · Total reported value $1.87B · Top-10 concentration 59.4% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 22.7% · 6 new · 1 cut · 3 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +20.6% · vs SPY +5.8% · Prev Value $3.89B — last quarter positions weighted by this quarter price moves · ranking
In its Q4 2023 13F filing, Frazier Life Sciences Management, L.P. disclosed 49 equity positions with a combined reported value of $1.87B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 59.4% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2023 were MIRM ($191.74M), HLVX ($156.99M), NAMS ($135.51M). By sector, the heaviest allocations are Health Care 71.1%, Materials 0.1%. Versus the prior quarter, allocation shifted toward Other (+2.1pp) and away from Health Care (-2.1pp).
Versus the prior quarter, Frazier Life Sciences Management, L.P. opened 6 new positions, trimmed 1 and fully exited 3, a turnover rate of 22.7% of positions. The portfolio's overlap with the prior quarter was 79% of names.
The largest new positions opened in Q4 2023 were ETNB ($22.34M), MDGL ($16.06M), DYN ($15.76M).
Of the 3 positions fully exited versus the prior quarter, the largest were ELVN ($14.35M), REPL ($6.62M), PRTA ($6.17M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2023)
- ETNB 89BIO INC · $22.34M
- MDGL MADRIGAL PHARMACEUTICALS INC · $16.06M
- DYN DYNE THERAPEUTICS INC · $15.76M
- GPCR STRUCTURE THERAPEUTICS INC · $12.93M
- MRTX MIRATI THERAPEUTICS INC · $4.70M
Fully Exited (vs previous quarter)
- ELVN ENLIVEN THERAPEUTICS INC · prev qtr: $14.35M
- REPL REPLIMUNE GROUP INC · prev qtr: $6.62M
- PRTA PROTHENA CORP PLC · prev qtr: $6.17M
- STRO SUTRO BIOPHARMA INC · prev qtr: $2.71M
- SNDX SYNDAX PHARMACEUTICALS INC · prev qtr: $1.57M
- ADCT ADC THERAPEUTICS SA · prev qtr: $1.48M
- PASG Passage Bio Inc · prev qtr: $1.16M
Insider Transactions (Form 4)
Latest Frazier Life Sciences Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Frazier Life Sciences Management, L.P. is an SEC-registered 13F filer. As of Q2 2026 it reported 41 US equity positions with a combined value of $4.59B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
- 41 positions · $4.59B reported value (Q2 2026)
- Top 10 holdings = 73.6% of reported value
- Largest position: MIRM (MIRUM PHARMACEUTICALS INC) at 19.6%
- Average position size: $112.00M
Sector Tilt
- Health Care 99.8%
- Materials 0.2%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 6 new, 8 added, 1 reduced, 3 exited
- 26 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
6.50M | $191.74M | 10.25% | Hold | |
| 2 |
|
9.78M | $156.99M | 8.39% | Hold | |
| 3 |
|
12.13M | $135.51M | 7.25% | Hold | |
| 4 |
|
988.46K | $122.63M | 6.56% | Hold | |
| 5 |
|
2.73M | $110.05M | 5.88% | Hold | |
| 6 |
|
2.37M | $109.01M | 5.83% | Hold | |
| 7 |
|
10.11M | $92.30M | 4.93% | Hold | |
| 8 |
|
1.16M | $73.12M | 3.91% | Hold | |
| 9 |
|
3.01M | $59.93M | 3.20% | Hold | |
| 10 |
|
3.13M | $59.68M | 3.19% | Add | |
| 11 |
|
885.16K | $52.99M | 2.83% | Add | |
| 12 |
|
1.52M | $45.64M | 2.44% | Add | |
| 13 |
|
785.00K | $45.34M | 2.42% | Add | |
| 14 |
|
3.62M | $44.37M | 2.37% | Add | |
| 15 |
|
1.79M | $36.20M | 1.94% | Hold | |
| 16 |
|
2.67M | $29.18M | 1.56% | Add | |
| 17 |
|
997.46K | $28.61M | 1.53% | Hold | |
| 18 |
|
1.39M | $28.46M | 1.52% | Hold | |
| 19 |
|
8.76M | $28.31M | 1.51% | Add | |
| 20 |
|
1.20M | $27.27M | 1.46% | Hold | |
| 21 |
|
3.75M | $24.13M | 1.29% | Hold | |
| 22 |
|
2.40M | $23.10M | 1.24% | Add | |
| 23 |
|
730.92K | $22.89M | 1.22% | Add | |
| 24 |
|
2.00M | $22.34M | 1.19% | New | |
| 25 |
|
746.48K | $20.53M | 1.10% | Hold | |
| 26 |
|
2.14M | $19.71M | 1.05% | Hold | |
| 27 |
|
899.70K | $19.27M | 1.03% | Hold | |
| 28 |
|
4.00M | $18.80M | 1.00% | Hold | |
| 29 |
|
464.94K | $18.71M | 1.00% | Hold | |
| 30 |
|
393.00K | $16.66M | 0.89% | Hold | |
| 31 |
|
1.02M | $16.48M | 0.88% | Add | |
| 32 |
|
69.41K | $16.06M | 0.86% | New | |
| 33 |
|
1.18M | $15.76M | 0.84% | New | |
| 34 |
|
881.17K | $15.31M | 0.82% | Hold | |
| 35 |
|
1.03M | $14.22M | 0.76% | Hold | |
| 36 |
|
397.48K | $14.14M | 0.76% | Reduce | |
| 37 |
|
317.19K | $12.93M | 0.69% | New | |
| 38 |
|
285.33K | $11.74M | 0.63% | Hold | |
| 39 |
|
2.00M | $11.73M | 0.63% | Add | |
| 40 |
|
523.17K | $11.65M | 0.62% | Add | |
| 41 |
|
400.00K | $11.18M | 0.60% | Hold | |
| 42 |
|
7.38M | $9.89M | 0.53% | Add | |
| 43 |
|
2.12M | $8.58M | 0.46% | Reduce | |
| 44 |
|
203.68K | $6.21M | 0.33% | Hold | |
| 45 |
|
80.00K | $4.70M | 0.25% | New | |
| 46 |
|
1.71M | $2.36M | 0.13% | Hold | |
| 47 |
|
1.03M | $2.10M | 0.11% | Reduce | |
| 48 |
|
500.33K | $1.57M | 0.08% | Hold | |
| 49 |
|
264.38K | $277.60K | 0.01% | Hold | |
FAQ
What did Frazier Life Sciences Management, L.P. buy in 2023-Q4?
In its 2023-Q4 13F filing, Frazier Life Sciences Management, L.P. reported 49 equity positions worth $1.87B in aggregate; its largest disclosed positions were MIRM ($191.74M), HLVX ($156.99M), NAMS ($135.51M).
How large is Frazier Life Sciences Management, L.P.'s portfolio?
Frazier Life Sciences Management, L.P. reported $1.87B of long equity holdings across 49 positions as of 2023-Q4. Top-10 holdings account for 59.4% of reported value.
What is Frazier Life Sciences Management, L.P.'s investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.